IP Verse

Amgen (europe) Gmbh opposition analysis

COMPANY ANALYSIS

Latest patents of Amgen (europe) Gmbh opposed by its competitors

Patent:
EP2651400
Grant Date:
Jan 18, 2023
Title:
Controlled Release Oral Dosage Forms Of Poorly Soluble Drugs And Uses Thereof
Oppositions:
1
Patent:
EP3320902
Grant Date:
Feb 17, 2021
Title:
Methods For Treating Diseases Using Isoindoline Compounds
Oppositions:
1
Patent:
EP2797581
Grant Date:
May 6, 2020
Title:
Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-Dione
Oppositions:
3
Patent:
EP2687213
Grant Date:
Jul 17, 2019
Title:
Solid Forms Comprising (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione, Compositions Thereof, And Uses Thereof
Oppositions:
1
Patent:
EP2223688
Grant Date:
May 29, 2019
Title:
(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof
Oppositions:
5
Patent:
EP2962690
Grant Date:
Jan 16, 2019
Title:
(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof
Oppositions:
15

Competitors of Amgen (europe) Gmbh

GALENICUM HEALTH S.L.U.

TEVA PHARMACEUTICAL INDUSTRIES LTD.

GENERICS (UK) LTD

Want to track Amgen (europe) Gmbh?

Feel free to send us a message here and we will get back to you